FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 47, No. 5, 2009
pp. S67-S74

Review article

Adverse effects of endocrine disruptors on the foetal testis development: focus on the phthalates

René Habert[1,2,3], Vincent Muczynski[1,2,3], Abdelali Lehraiki[1,2,3], Romain Lambrot[1,2,3], Charlotte Lécureuil[1,2,3], Christine Levacher[1,2,3], Hervé Coffigny[1,2,3], Catherine Pairault[1,2,3], Delphine Moison[1,2,3], René Frydman[4] and Virginie Rouiller-Fabre[1,2,3]

[1]Laboratory of Differentiation and Radiobiology of the Gonads, CEA – DSV / iRCM / SCSR, F-92265 Fontenay aux Roses, France
[2]Université Paris Diderot-Paris7, F-92265, Fontenay aux Roses, France
[3]INSERM, Unité 967, F-92265, Fontenay aux Roses, France
[4]Service de Gynécologie-Obstétrique, Université Paris Sud, Hôpital A. Béclere, F-92141 Clamart, France

Abstract: There are great concerns about the increasing incidence of abnormalities in male reproductive function. Human sperm counts have markedly dropped and the rate of testicular cancer has clearly augmented over the past four decades. Moreover, the prevalence rates of cryptorchidism and hypospadias are also probably increasing. It has been hypothesized that all these adverse trends in male reproduction result from abnormalities in the development of the testis during foetal and neonatal life. Furthermore, many recent epidemiological, clinical and experimental data suggest that these male reproductive disorders could be due to the effects of xenobiotics termed endocrine disruptors, which are becoming more and more concentrated and prevalent in our environment. Among these endocrine disruptors, we chose to focus this review on the phthalates for different reasons: 1) they are widespread in the environment; 2) their concentrations in many human biological fluids have been measured; 3) the experimental data using rodent models suggesting a reprotoxicity are numerous and are the most convincing; 4) their deleterious effects on the *in vivo* and *in vitro* development and function of the rat foetal testis have been largely studied; 5) some epidemiological data in humans suggest a reprotoxic effect at environmental concentrations at least during neonatal life. However, the direct effects of phthalates on human foetal testis have never been explored. Thus, as we did for the rat in the 1990s, we recently developed and validated an organ culture system which allows maintenance of the development of the different cell types of human foetal testis. In this system, addition of 10^{-4} M MEHP (mono-2-ethylhexyl phthalate), the most produced phthalate, had no effect on basal or LH-stimulated production of testosterone, but it reduced the number of germ cells by increasing their apoptosis, without modification of their proliferation. This is the first experimental demonstration that phthalates alter the development of the foetal testis in humans. Using our organotypic culture system, we and others are currently investigating the effect of MEHP in the mouse and the rat, and it will be interesting to compare the results between these species to analyse the relevance of toxicological tests based on rodent models.

Key words: endocrine disruptors, phthalates, environment, development, reproduction, health, foetus, testis, germ cells, testosterone

Alterations in male reproductive function

Changes in the environment and their consequences for male reproductive function have been of major concern for the past 20 years [1-3].

Correspondence: R. Habert, Laboratory of Differentiation and Radiobiology of the Gonads, CEA – DSV/iRCM/SCSR, F-92265 Fontenay aux Roses, France; tel.: 00 1 46 549499, fax.: 00 1 46 54 99 06, e-mail: rene.habert@cea.fr

Alterations in male reproduction were first observed in wild animals, in studies reporting the effects of accidental exposure of estrogenic chemicals on wildlife in the natural environment. These changes in male reproductive function vary from very subtle to permanent alterations, such as feminization or changes in reproductive behaviour [2,4]. Guillette *et al* studied the male reproductive function of alligators in two lakes in Florida. These two lakes are located very close

Folia Histochem Cytobiol. 2009:47(5): S67 (S67-S74)
10.2478/v10042-009-0056-5

to each other geographically, excluding the possibility of climate-based bias in these studies. They found that adult male alligators in Apopka Lake, which was polluted with agricultural waste and experienced a major chemical spill in 1980, had lower testosterone levels and presented micropenis and disorganized testes [5,6]. A key part of this story is that no chemicals could be detected in the water of the apparently contaminated lake and thus the alligators were being exposed simply by being at the top of the food chain. Other documented disruptions or alterations of reproductive activity and physiology have been correlated with exposure of contaminants in fish, amphibians, reptiles, birds, and mammals [4,7,8]. Most of the reported effects on wildlife have been observed on aquatic organisms and this is linked to the concentration of pollutants along the food chain. In humans, there is increasing evidence that the birth sex ratio is altered in areas close to industry and exposed to environmental and industrial chemicals. The findings of the recent report on the Aamjiwnaang First Nation community in Canada are striking [9], i.e. the proportion of male live births in this community has been decreasing continually from 1990 to 2003, the sex ratio (number of male births/total number of births) being only 0.3.

The epidemiologic data have also shown an increase in human male reproductive function disorders over the past 50 years, with the suggestion of a relation with the increase in the amounts of endocrine disruptors in the environment. Testicular cancer, which is the most prevalent cancer in young men, has steadily increased in all countries studied, rising, for example, from 3.4 per 10,000 in 1973 to 5.5 per 10,000 in 1997 in North America [10]. Hypospadias and cryptorchidism also dramatically increased from 0.2 and 2%, respectively, in 1970 to 0.38 and 3.5%, respectively, in 1991 [10]. Finally, sperm count decline has been controversial, but large-scale prospective studies using standardized methodologies have shown a decline from 170 to 70 million spermatozoa per millilitre between 1940 and 1990 in Europe [1,11].

There are grounds for linking these four types of disorders. For example, a comparative study in European countries showed that the incidence of each of these four pre-cited abnormalities (sperm count decline, testicular cancer, hypospadias, and cryptorchidism) was maximal in Denmark and minimal in Finland [12]. Moreover, a history of cryptorchidism increases the risk of other three disorders [13], by a factor of 3-17 in the case of testicular cancer [14]. Similarly, hypospadias increases the chances of developing testicular cancer [1], and oligospermia is frequently observed in men who go on to develop testicular cancer [15,16]. Therefore, it has been suggested that these four alterations are symptoms of a single syndrome named the testicular dysgenesis syndrome (TDS) [16,17].

These abnormalities first arise during foetal development

The foetal testis is formed by the mixing of a somatic anlage growing at the surface of the mesonephros and primordial germ cells that colonize the gonad and are called gonocytes (reviews in [18], Rouiller-Fabre *et al* in this issue). The foetal testis carries out crucial endocrine and gametogenic functions. Foetal Leydig cells produce the testosterone and insulin-like factor 3 (Insl3), which are absolutely necessary for phenotypic masculinisation of the embryo [19], (review in [20]). After birth, gonocytes give rise to the adult stem spermatogonia and thus correct development of the germ cell lineage during foetal/embryonic life is essential for the establishment of the ability of the individual to produce spermatozoa throughout his life.

It is currently thought that TDS is probably caused by disturbances in the development of the foetal testis [16] because the origins of all four characteristics of TDS can be traced to foetal development.

Hypospadias results from defects in androgen production or action during foetal development, while cryptorchidism results from abnormalities in the production and/or activity of Insl3 and/or the androgens respectively regulating the transabdominal and transinguinal descent of the testes [19].

The aetiology of testicular cancer remains unclear, but there is considerable evidence to suggest that it originates early in development [17] when gonocytes would normally have differentiated into spermatogonia. Carcinoma in situ (CIS) is a local malignant lesion that precedes testicular cancer (seminomas and non-seminomas) [21]. CIS cells closely resemble foetal germ cells in terms of morphology and immunohistological markers (c-kit, alkaline phosphatase, etc) [22]. Moreover, CIS has been reported in boys only a few months old [16].

Finally, sperm counts may have decreased for multiple reasons as the regulation of spermatogenesis remains poorly understood, but is known to involve complex endocrine, intratesticular, and intracellular regulation processes. The stock of gonocytes is determined during foetal development and takes part in determining the number of germ stem cells present in adulthood, since experimentally induced decreases in the number of gonocytes during foetal development lead to decreases in sperm count in adulthood [23,24] Similar results are obtained if the number of Sertoli cells is reduced during perinatal life [25]. Thus, adult sperm production depends partly on foetal seminiferous development.

Numerous clinical, epidemiological and experimental data support the hypothesis that TDS is caused by endocrine disruptors acting during foetal or neonatal life (reviews in [2], [26-28]). Endocrine disruptors have been quantitatively and qualitatively increasing

Folia Histochem Cytobiol. 2009:47(5): S68 (S67-S74)
10.2478/v10042-009-0056-5

in our environment during the last decades. They originate from various sources including plants (phytoestrogens), agriculture (insecticides, herbicides, fumigants and fungicides) and many chemicals (pharmaceutical products, plasticisers, resins, detergents, PCB, flame retardant, bisphenol A, antimicrobial parabens, dioxins). In the present study we focused on phthalates.

Environmental exposure to phthalates

Phthalates (phthalic acid esters) are industrial chemicals that have been used increasingly since 1930. Their worldwide production grew from 1.8 to 4.3 million tons between 1970 and 2006. Phthalates are plasticisers that are added to polymers and essentially to PVC to make them softer and more flexible. They are widely used in a wide range of soft-PVC products including building and construction materials such as cabling, flooring, wall covering, profiles and roofs. They are components of medical equipment, hoses, shower curtains, films and plastic gloves, household furnishings, toys, car interiors, clothing, food and beverage packaging, pharmaceutical products, etc. Phthalates are also used as solvents for oil-soluble dyes, insecticides, peroxides, and other organics. They are added to paints and lacquers, adhesives and sealants, cosmetics, lubricants, putty, perfumes, deodorants, sprays. Di(2-ethylhexyl) phthalate (DEHP) is the most widely used phthalate. One and half million tons of DEHP are produced every year worldwide (40% in Europe). Phthalates are not covalently bound to the product matrix and can leach out over time from these products. As an example, they are recovered in domestic dust [29]. Dermal exposure via clothes and cosmetics may also occur. Small population groups may be exposed via medical equipment. So humans are constantly exposed to phthalates through oral, dermal and inhalation routes [30,31]. In the body, phthalates are rapidly hydrolyzed by esterases in the gut and other tissues into monoesters, which are the active molecules [32]. For example, DEHP is metabolized to its monoester metabolite, mono-(2-ethylhexyl) phthalate (MEHP), and DBP is converted into mono-butyl phthalate (MBP).

Whereas many endocrine disruptors are persistent in the environment and accumulate in fat, the half-life of phthalates does not exceed 36 h in the body. In humans, 75% of the DEHP ingested is metabolized and excreted in urine within 2 days [33]. However, phthalates are so widespread in the environment that humans are largely exposed. As an example, according to a study published in 2003, 12% of the German population has a daily intake of DEHP that exceeds European recommendations [34]. In an epidemiologic study, 75% of the 289 human subjects tested were positive for the presence of four different types of phthalates in their urine samples [35]. The concentration of phthalates in biological fluids in humans show large individual variations [36-41]. Values for MEHP are reported in Table 1. Values for MBP are similar or higher, and its urinary concentration in pregnant mothers can reach 5.10^{-6} M. The most recent reports indicate median levels in urine and amniotic fluid of 4.10^{-7} M for MBP and 8.10^{-8} M for MEHP [41].

Effects of phthalates on the development of the rat testis

The first observation of phthalate-induced testicular injuries was reported using adult rats in 1945 [42]. The oral administration of DEHP at dietary concentrations of 0.075, 0.75, 1.5 and 5.0% to rats for 90 days resulted in tubular atrophy and testicular degeneration at the two top dose levels. Subsequently, Harris *et al*. found occasional incidence of tubular atrophy in rats fed 0.5% DEHP in the diet for periods of 3 or 24 months [43]. Many other confirmed and explored the testicular effects of phthalate in experimental animals (review in [44]).

Numerous studies in the rat foetus have shown that *in utero* exposure to di (n-butyl) phthalate (DBP) or DEHP [27,45]). Much attention has been paid to the analysis of Leydig cell development and function [46-52]. *In utero* exposure to phthalates induces an abnormal aggregation of the foetal Leydig cells, an occurrence of intratubular Leydig cells, a reduction of foetal testosterone production and Leydig cell Insl3 gene expression. This leads to epididymal agenesis, reduced ano-genital distance, hypospadias and cryptorchidism. Furthermore, *in utero* exposure to phthalates induces subnormal Sertoli cell proliferation [53], and possibly function [54,55]. Lastly, formation of multinucleated gonocytes during neonatal life and impaired spermatogenesis/infertility in adult have been observed [54,56]. Thus *in utero* exposure to phthalate results in a TDS-like syndrome in the male offspring, except for testicular cancer which is not induced.

The *in vitro* approach has also been used for time and dose analyses of the effects of phthalates on the rat foetal testis. The main limitation on the toxicological use of *in vitro* studies is that the activities and fates of the cells *in vitro* must reproduce those existing *in vivo*. In mammalian cell culture systems, foetal Leydig cells dedifferentiate in the absence of specific gonadotropic stimulation [57-59]. Isolated gonocytes display poor survival in such systems [60-62]. Organ culture systems preserving testicular architecture and intercellular communications appear to us as a relevant method to maintain the development of the foetal, embryonic or neonatal testis. Furthermore, one testis can be cultured in the presence of the tested molecule whereas

Folia Histochem Cytobiol. 2009:47(5): S69 (S67-S74)
10.2478/v10042-009-0056-5

Table 1. Concentrations of MEHP in differents biological fluids in human

Biological liquid	Mininal concentration	Maximal concentration	Reference
Urina from pregnant women	5.10^{-9} M	8.10^{-8} M	Silva et al. 2004 [37]
Urine from pregnant women	5.10^{-9} M	3.10^{-8} M	Swan et al. 2005 [38]
Urine from pregnant women	2.10^{-8} M	5.10^{-7} M	Huang et al. 2009 [41]
Amniotic fluid	$< 3.10^{-9}$ M	4.10^{-7} M	Huang et al. 2009 [41]
Blood from the umbilical cord	not detectable	8.10^{-6} M	Latini et al. 2003 [36]
Human milk	5.10^{-9} M	5.10^{-6} M	Main et al. 2006 [39]
Human milk	2.10^{-9} M	2.10^{-8} M	Högberg et al. 2008 [40]
Human serum from nursing mothers	2.10^{-9} M	2.10^{-8} M	Högberg et al. 2008 [40]
Human urine from nursing mothers	10^{-8}M	2.10^{-7} M	Högberg et al. 2008 [40]

the contralateral testis is cultured in its absence. Thus, an original technique using a filter system was been set up by Habert's team in 1991 [63] (Fig 1). This technique reproduces the development of the Leydig, Sertoli and germ cells observed *in vivo* [58,59,64-67]. Thus, this organotypic culture system is an important tool to study the age-, time- and dose-dependent direct effects of endocrine disruptors on the development of the foetal testis [67]. We named this method the rat foetal testis assay (rFETA) Then, we extended this method to mouse and human foetal testis [66,68-70] and named the methods mFETA and hFETA, respectively. Using this system, the effects of MBP and MEHP were investigated in the rat [71-74]. When explanted at 13.5 or 14.5 days post partum (dpc), one group found an MEHP-induced decrease in the number of gonocytes, and in the production of testosterone and AMH [74] which were not observed by others [72,73]. The reasons for these discrepancies are unclear, but are probably linked to experimental conditions. With foetal testes explanted at 18.5-19.5 dpc, MEHP or MBP induced reductions in the proliferation and AMH expression of Sertoli cells and a reduction in LH-stimulated testosterone production [71,72]. At 3 days post partum, when proliferation of the gonocytes resumes, MEHP induced apoptosis in this cell type [72].

Effects of phthalates on the development of human foetal testis

Despite the growing body of literature data on phthalate reproductive toxicity in animal models, and data demonstrating extensive human exposure, very few studies have examined the effects of these chemicals on human reproductive development.

Epidemiological studies are highly difficult to perform because of the numerous factors that can act on foetal testis development, including hundreds of endocrine disruptors, alcohol, tobacco, individual stress. Furthermore, it is important to take into account the period of exposure. For instance, an association between a low sperm count in adult men with the treatment of their mother with diethylstilbestrol (DES) during pregnancy can be demonstrated only if the data relate to treatment during the first trimester [75]. Recently, anogenital distance was chosen in humans as an index of masculinisation and therefore an index of androgenic activity of the testis. An inverse correlation has been found between anogenital distance measured in male infants 2-36 months of age (mean 12.6 months) and maternal urinary concentrations of MBP and 3 other monoester phthalate metabolites measured at the end of pregnancy [38]. Interestingly, no correlation was observed for MEHP. In the same way, a concentration-dependent association between phthalates in breast milk and levels of reproductive hormones in boys at 3 months of age was also reported [39]. However, a recent paper by Huang *et al* 2009 reported no association between the anogenital distance measured in boys at birth and the concentration of any phthalates in the amniotic fluid or maternal urine during pregnancy. Taken together, these epidemiological studies suggest that some phthalates at environmental concentrations have antiandrogenic effects during neonatal life. Their antiandrogenic effects during foetal life are not demonstrated.

Recently our team reported the first experimental demonstration of the potential deleterious effect of phthalates on human testis function or development [76]. In this study, we used the organ culture system of human foetal testes that we developed previously coupled with morphologic, functional, and molecular methods [68-70] to analyse the effects of MEHP on the development of testicular somatic and germ cells during the first trimester of pregnancy (Fig 1). This early developmental period of the testis has been shown to be a critical window for the determination of the reproductive tract [77].

Folia Histochem Cytobiol. 2009:47(5): S70 (S67-S74)
10.2478/v10042-009-0056-5



Fig. 1. Human foetal testis assay in humans (hFETA): One testis is cultured after fragmentation in the presence of the test compound and the other one from the same foetus is cultured in the absence of the test compound and served as control. MEHP was assayed and microphotographs show the reduction of the number of gonocytes after 3 days of culture in the presence of 10^{-4} M MEHP [76]. Gonocytes are identified as white cells inside the seminiferous cords, while the Sertoli cells have been immunostained for anti-Müllerian hormone.

Human foetal testes were recovered during the first trimester (7-12 weeks) of gestation and cultured for 3 days with or without MEHP in basal conditions or stimulated with luteinizing hormone (LH). Whatever the dose, MEHP treatment had no effect on basal or LH-stimulated testosterone produced by the human foetal testis *in vitro*. MEHP treatment did not affect the mRNA expression of P450c17, P450scc, or StAR, or that of Insl3 produced by foetal Leydig cells, which is known to be involved in testicular descent and the expression of the steroidogenic enzymes. MEHP (10^{-4} M) did not affect proliferation or apoptosis of Sertoli cells, but it reduced the mRNA expression of anti-Müllerian hormone. Interestingly, MEHP (10^{-4} M) reduced the number of germ cells by increasing their apoptosis, measured by the detection of caspase-3-positive germ cells, without modification of their proliferation.

Conclusions

We review here arguments suggesting that the alterations of the male reproductive functions observed during the last decades are linked to an increasing exposure to endocrine disruptors with a focus on the phthalates. Our laboratory recently here the first experimental evidence for the potential of phthalates to impair the development of foetal testis in the human species [76]. Interestingly, the main disruption appears to be of the gametogenic function of the foetal testis, and no effect was observed on Leydig cell development and function. In the same way, epidemiological studies suggest that the antiandrogenic effects of environmental phthalates occur in the baby or the young child and not during foetal life. In rats, as in humans, phthalates act on foetal/neonatal gametogenesis, but, unlike in humans, they induce large antiandrogenic effects. Thus, the relevance of the rat model for toxicological studies related to phthalates must be debated. A recent paper reports that *in utero* exposure to phthalates impairs the development of gametogenesis without alterations of steroidogenesis of the foetal testis in mouse [78]. Using mouse foetal testis in culture, we also observed impairment of gametogenesis and no decrease of steroidogenesis [79]. Thus it will be important to establish whether the mouse could be an interesting model for studying the effects and mechanisms of action of phthalates in human foetal testicular development.

Acknowledgements: This work was supported by Université Paris Diderot-Paris 7, CEA, INSERM, the Agence Française pour la Santé et la Sécurité dans l'Environnement et le Travail (AFSSET)

Folia Histochem Cytobiol. 2009:47(5): S71 (S67-S74)
10.2478/v10042-009-0056-5

and the Agence Nationale pour la Recherche (ANR). V.M. and A.L. hold fellowships from the Ministere de l'Education Nationale de la Recherche et de la Technologie. R.L. was the recipient of a fellowship from the Commissariat a l'Energie Atomique. We thank the staff of the Department of Obstetrics and Gynecology of the Antoine Béclere Hospital (Clamart, France). We thank Aurélie Gouret for her skilful secretarial assistance. This review is dedicated to my mentor, JM Saez.

References

[1] Sharpe RM, Irvine DS. How strong is the evidence of a link between environmental chemicals and adverse effects on human reproductive health? *BMJ*. 2004;328:447-451.
[2] Delbes G, Levacher C, Habert R. Estrogen effects on fetal and neonatal testicular development. *Reproduction*. 2006;132: 527-538.
[3] Leridon H, Slama R. The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology. *Hum Reprod*. 2008;23:1312-319.
[4] Vos JG, Dybing E, Greim HA, Ladefoged O, Lambre C, Tarazona JV, Brandt I, Vethaak AD. Health effects of endocrine-disrupting chemicals on wildlife, with special reference to the European situation. *Crit Rev Toxicol*. 2000;30:71-133.
[5] Guillette LJ Jr, Gross TS, Masson GR, Matter JM, Percival HF & Woodward AR. Developmental abnormalities of the gonad and abnormal sex hormone concentrations in juvenile alligators from contaminated and control lakes in Florida. *Environ Health Perspect*. 1994;102:680-688.
[6] Guillette LJ Jr, Guillette EA. Environmental contaminants and reproductive abnormalities in wildlife: implications for public health? *Toxicol Industr Health*. 1996;12:537-550.
[7] Oskam IC, Ropstad E, Dahl E, Lie E, Derocher AE, Wiig O, Larsen S, Wiger R & Skaare JU. Organochlorines affect the major androgenic hormone, testosterone, in male polar bears (Ursus maritimus) at Svalbard. *J Toxicol Environ Health*.. 2003;Part A 66:2119-2139.
[8] Edwards TM, Moore BC, Guillette LJ Jr. Reproductive dysgenesis in wildlife: a comparative view. *Int J Androl*. 2006; 29:109-121.
[9] Mackenzie CA, Lockridge A, Keith M. Declining sex ratio in a first nation community. *Environ Health Perspect*. 2005;113:1295-1298.
[10] Toppari J. Environmental endocrine disrupters and disorders of sexual differentiation. *Semin Reprod Med.* 2002;20:305-312.
[11] Auger J, Kunstmann JM, Czyglik F, Jouannet P. Decline in semen quality among fertile men in Paris during the past 20 years. *NEJM*. 1995;332:281-285.
[12] Virtanen HE, Rajpert-De Meyts E, Main KM, Skakkebaek NE, Toppari J. Testicular dysgenesis syndrome and the development and occurrence of male reproductive disorders. *Toxicol Applied Pharmacol*. 2005;207 501-505.
[13] Kaleva M, Virtanen HE, Haavisto AM, Main KM, Reunanen M, Skakkebaek NE & Toppari J. Circannual rhythm in the incidence of cryptorchidism in Finland. *Int J Androl*. 2005;28 53-57.
[14] Davenport M. Risk of testicular cancer in boys with cryptorchidism. Study was based on small number of cancers. *BMJ*. 1997;315:1462-1463.
[15] Moller H & Skakkebaek NE. Risk of testicular cancer in subfertile men: case-control study. *BMJ*. 1999;318:559-562.
[16] Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. *Human Reprod*. 2001;16: 972-978.
[17] Skakkebaek NE, Jorgensen N. Testicular dysgenesis and fertility. *Andrologia*. 2005;37:217-218.
[18] Olaso R, Habert R. Genetic and cellular analysis of male germ cell development. *J Androl*. 2000;21:497-511.
[19] Kubota Y, Temelcos C, Bathgate RA, Smith KJ, Scott D, Zhao C, Hutson JM. The role of insulin 3, testosterone, Mullerian inhibiting substance and relaxin in rat gubernacular growth. *Mol Human Reprod*. 2002;8:900-905.
[20] Habert R, Lejeune H & Saez JM. Origin, differentiation and regulation of fetal and adult Leydig cells. *Mol Cell Endocrinol*. 2001;179:47-74.
[21] Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. *Clin Endocrinol*. 1981;14:49-61.
[22] Meyts E, Jorgensen N, Brondum-Nielsen K, Muller J, Skakkebaek NE. Developmental arrest of germ cells in the pathogenesis of germ cell neoplasia. *APMIS*. 1998;106:198-204 (Discussion 204-196).
[23] Moreno SG, Dutrillaux B, Coffigny H. Status of p53, p21, mdm2, pRb proteins, and DNA methylation in gonocytes of control and gamma-irradiated rats during testicular development. *Biol Reprod* 2001;64:1422-1431.
[24] Forand A, Messiaen S, Habert R, & Bernardino-Sgherri J. Exposure of the mouse perinatal testis to radiation leads to hypospermia at sexual maturity Reproduction. (in press).
[25] Orth JM, Gunsalus GL, Lamperti A. Evidence from sertoli celldepleted rats indicates that spermatid number in adults depends on numbers of sertoli cells produced during perinatal development. *Endocrinology*. 1988;122:787-794.
[26] Sharpe RM. Pathways of endocrine disruption during male sexual differentiation and masculinization. *Best Pract Res Clin Endocrinol Metab*. 2006;20:91-110.
[27] Sharpe RM, Skakkebaek NE. Testicular dysgenesis syndrome: mechanistic insights and potential new downstream effects. *Fertil Steril*. 2008;89(2 Suppl):33-38.
[28] Wohlfahrt-Veje C, Main KM, Skakkebć k NE. Testicular Dysgenesis Syndrome; Fetal origin of adult reproductive problems. *Clin Endocrinol (Oxf)*. 2009 Feb 16. [Epub ahead of print]
[29] Becker K, Seiwert M, Angerer J, Heger W, Koch HM, Nagorka R, Rosskamp E, Schlüter C, Seifert B, Ullrich D. DEHP metabolites in urine of children and DEHP in house dust. *Int J Hyg Environ Health*. 2004;207:409-417.
[30] Koch HM, Preuss R, Angerer J. Di(2-ethylhexyl)phthalate (DEHP): human metabolism and internal exposure-- an update and latest results. *Int J Androl*. 2006;29:155-165.
[31] Wormuth M, Scheringer M, Vollenweider M, Hungerbuhler K. What are the sources of exposure to eight frequently used phthalic acid esters in Europeans? *Risk Anal*. 2006;26:803-824.
[32] Latini G. Monitoring phthalate exposure in humans. *Clin Chim Acta*. 2005;361:20-29.
[33] Koch HM, Bolt HM, Preuss R, Angerer J. New metabolites of di(2- ethylhexyl)phthalate (DEHP) in human urine and serum after single oral doses of deuteriumlabeled DEHP. *Arch Toxicol*. 2005;79:367-376.
[34] Koch HM, Drexler H, Angerer J. An estimation of the daily intake of di(2- ethylhexyl)phthalate (DEHP) and other phthlates in the general population. *Int J Hyg Environ Health*. 2003;206:77-83.
[35] Blount BC, Silva MJ, Caudill SP, Needham LL, Pirkle JL, Sampson EJ, *et al*. Levels of seven urinary phthalate metabolites in a human reference population. *Environ Health Perspect*. 2000;108:979-982.
[36] Latini G, De Felice C, Presta G, Del Vecchio A, Paris I, Ruggieri F, Mazzeo P. *In utero* exposure to di-(2-ethylhexyl)phthalate and duration of human pregnancy. *Environ Health Perspect*. 2003;111:1783-1785.

[37] Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, *et al*. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. *Environ Health Perspect*. 2004;112:331-338.
[38] Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S *et al*. Decrease in anogenital distance among male infants with prenatal phthalate exposure. *Environ Health Perspect*. 2005; 113:1056-1061.
[39] Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen DV, Andersson AM, Toppari J, Skakkebaek NE. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. *Environ Health Perspect*. 2006;11:270-276.
[40] Högberg J, Hanberg A, Berglund M, Skerfving S, Remberger M, Calafat AM, Filipsson AF, Jansson B, Johansson N, Appelgren M, Hakansson H. Phthalate diesters and their metabolites in human breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations. *Environ Health Perspect*. 2008;116:334-339.
[41] Huang PC, Kuo PL, Chou YY, Lin SJ, Lee CC. Association between prenatal exposure to phthalates and the health of newborns. *Environ Int.* 2009;35:14-20.
[42] Shaffer CB, Carpenter CP, Smyth HR Jr. Acute and subacute toxicity of di-(2-ethylhexyl)phthalate with note upon its metabolism. *J Ind Hyg Toxicol*. 1945;27:130-135.
[43] Harris RS, Hodge HC, Maynard ER and Blancher HJ Jr. Chronic oral toxicity of 2-ethylhexyl phthalate in rats and dogs. *Arch Ind Hyg*. 1956;13:259-264.
[44] Gangolli SD. Testicular effects of phthalate esters. *Environ Health Perspect*. 1982;45:77-84.
[45] Foster PM. Disruption of reproductive development in male rat offspring following *in utero* exposure to phthalate esters. *Int J Androl.* 2006;29:140-147; discussion 181-145.
[46] Mylchreest E, Wallace DG, Cattley RC, Foster PM. Dose-dependent alterations in androgen-regulated male reproductive development in rats exposed to Di(n-butyl) phthalate during late gestation. *Toxicol Sci*. 2000;55:143-151.
[47] Parks LG, Ostby JS, Lambright CR, Abbott BD, Klinefelter GR, Barlow NJ, *et al.* The plasticizer diethylhexyl phthalate induces malformations by decreasing fetal testosterone synthesis during sexual differentiation in the male rat. *Toxicol Sci*. 2000;58:339-349.
[48] Lehmann KP, Phillips S, Sar M, Foster PM, Gaido K. Dose-dependent alterations in gene expression and testosterone synthesis in the fetal testes of male rats exposed to di (n-butyl) phthalate. *Toxicol Sci*. 2004;81:60-68.
[49] Wilson VS, Lambright C, Furr J, Ostby J, Wood C, Held G, Gray LE, Jr. Phthalate ester-induced gubernacular lesions are associated with reduced insl3 gene expression in the fetal rat testis. *Toxicol Lett*. 2004;146:207-215.
[50] Mahood IK, Hallmark N, McKinnell C, Walker M, Fisher JS, Sharpe RM. Abnormal Leydig cell aggregation in the fetal testis of rats exposed to di (n-butyl) phthalate and its possible role in testicular dysgenesis. *Endocrinology*. 2005;146:613-623.
[51] McKinnell C, Sharpe RM, Mahood K, Hallmark N, Scott H, Ivell R, Staub C, Jegou B, Haag F, Koch-Nolte F, Hartung S. Expression of insulin-like factor 3 protein in the rat testis during fetal and postnatal development and in relation to cryptorchidism induced by *in utero* exposure to di (n-Butyl) phthalate. *Endocrinology*. 2005;146:4536-4544.
[52] Howdeshell KL, Wilson VS, Furr J, Lambright CR, Rider CV, Blystone CR, Hotchkiss AK, Gray LE Jr. A mixture of five phthalate esters inhibits fetal testicular testosterone production in the sprague-dawley rat in a cumulative, dose-additive manner. *Toxicol Sci*. 2008;105:153-165.
[53] Scott HM, Hutchison GR, Mahood IK, Hallmark N, Welsh M, de Gendt K, *et al*. Role of androgens in fetal testis development and dysgenesis. *Endocrinology* 2007;148:2027-2036.
[54] Fisher JS, Macpherson S, Marchetti N, Sharpe RM. Human "testicular dysgenesis syndrome": a possible model using in-utero exposure of the rat to dibutyl phthalate. *Hum Reprod*. 2003;18:1383-94.
[55] Fisher JS. Environmental anti-androgens and male reproductive health: focus on phthalates and testicular dysgenesis syndrome. *Reproduction*. 2004;127:305-315.
[56] Ferrara D, Hallmark N, Scott H, Brown R, McKinnell C, Mahood IK, Sharpe RM. Acute and long-term effects of *in utero* exposure of rats to di(n-butyl) phthalate on testicular germ cell development and proliferation. *Endocrinology*. 2006;147:5352-5362.
[57] Gautier C, Levacher C, Saez JM, Habert R. Transforming Growth Factor β1 inhibits steroidogenesis in dispersed fetal testicular cells in culture. *Mol Cell Endocrinol*. 1997;131:21-30.
[58] Rouiller-Fabre L, Carmona S, Abou-Merhi R, Cate R, Habert R, Vigier B. Effect of anti-Müllerian hormone (AMH) on Sertoli and Leydig cell functions in fetal and immature rats. *Endocrinology*. 1998;139:1213-1220.
[59] Rouiller-Fabre V, Lecerf L, Gautier C, Saez JM, Habert R. Expression and effect of Insulin-like Growth Factor I on rat fetal Leydig cell function and differentiation. *Endocrinology*. 1998;139:2926-2934.
[60] Van Dissel-Emiliani FM, de Boer-Brouwer M, Spek ER, van der Donk JA, de Rooij DJ. Survival and proliferation of rat gonocytes *in vitro. Cell Tissue Res*. 1993;273:141-147.
[61] Li H, Papadapoulos V, Vidic B, Dym M, Culty M. Regulation of rat testis gonocyte proliferation by platelet-derived growth factor and estradiol: identification of signaling mechanisms involved. *Endocrinology*. 1997;138:1289-1298.
[62] Boulogne B, Habert R, Levacher C. Regulation of the proliferation of cocultured gonocytes and Sertoli cells by retinoids, triiodothyronine, and intracellular signaling factors: differences between fetal and neonatal cells. *Mol Reprod Dev*. 2003;65:194-203.
[63] Habert R, Devif I, Gangnerau MN, Lecerf L. Ontogenesis of the *in vitro* response of rat testis to gonadotropin-releasing hormone. *Mol Cell Endocrinol*. 1991;82:199-206.
[64] Lecerf L, Rouiller-Fabre V, Levacher C, Gautier C, Saez J, Habert R. Stimulatory effect of follicle-stimulating hormone on basal and luteinizing hormone-stimulated testosterone secretion by fetal rat testis *in vitro. Endocrinology.* 1993; 133:2313-2318.
[65] Olaso R, Pairault C, Boulogne B, Durand P, Habert R. Transforming Growth Factor β1 and β2 reduce the number of gonocytes by increasing apoptosis. *Endocrinology*. 1998;139:733-740.
[66] Livera G, Rouiller-Fabre V, Durand P, Habert R. Multiple effects of retinoids on the development of Sertoli, germ and Leydig cells of fetal and neonatal rat testis in culture. *Biol Reprod.* 2000;62:1303-131.
[67] Livera G, Delbes G, Pairault C, Rouiller-Fabre V, Habert R. Organotypic culture, a powerful model for studying rat and mouse fetal testis development. *Cell Tissue Res*. 2006;324:507-521.
[68] Lambrot R, Coffigny H, Pairault C, Frydman R, Habert R, Rouiller-Fabre V. Use of organ culture to study the human fetal testis development: effect of retinoic acid. *J Clin Endoc Metab*. 2006;91:2696-2703.
[69] Lambrot R, Coffigny H, Pairault C, Frydman R, Habert R & Rouiller-Fabre V. High radiosensitivity of germ cells in human male fetus. *J Clin Endoc Metab*. 2007;92:2632-2639.
[70] Lambrot R, Livera G, Coffigny H, Pairault C, Frydman R, Habert R, Rouiller-Fabre V. A new method for toxicity assays on human and mouse fetal testis. *Biochimie*. 2006;88:1831-1835.

Folia Histochem Cytobiol. 2009:47(5): S73 (S67-S74)
10.2478/v10042-009-0056-5

[71] Hallmark N, Walker M, McKinnell C, Mahood IK, Scott H, Bayne R, Coutts S, Anderson RA, Greig I, Morris K, Sharpe RM. Effects of monobutyl and di(n-butyl) phthalate *in vitro* on steroidogenesis and Leydig cell aggregation in fetal testis explants from the rat: comparison with effects *in vivo* in the fetal rat and neonatal marmoset and *in vitro* in the human. *Environ Health Perspect*. 2007;115:390-396.
[72] Li H, Kim KH. Effects of mono-(2-ethylhexyl) phthalate on fetal and neonatal rat testis organ cultures. *Biol Reprod*. 2003; 69:1964-1972.
[73] Stroheker T, Regnier JF, Lassurguere J, Chagnon MC. Effect of *in utero* exposure to di-(2-ethylhexyl)phthalate: distribution in the rat fetus and testosterone production by rat fetal testis in culture. *Food Chem Toxicol*. 2006;44:2064-9.
[74] Chauvigné F, Menuet A, Lesné L, Chagnon MC, Chevrier C, Regnier JF, Angerer J, Jégou B. Time- and Dose-Related Effects of Di-(2-ethylhexyl) Phthalate and its Main Metabolites on the Function of the Rat Fetal Testis *in vitro*. *Environ Health Perspect.* in press.
[75] Storgaard L, Bonde JP, Olsen J. Male reproductive disorders in humans and prenatal indicators of estrogen exposure. A review of published epidemiological studies. *Cell Tissue Res.* 2006;21: 4-15.
[76] Lambrot R, Muczynski V, Lécureuil C, Angenard G, Coffigny H, Pairault C, Moison D, Frydman R, Habert R, Rouiller-Fabre V. Phthalates impair germ cell development in the human fetal testis *in vitro* without change in testosterone production. *Environ Health Perspect*. 2009;117:32-37.
[77] Welsh M, Saunders PT, Fisken M, Scott HM, Hutchison GR, Smith LB, *et al*. Identification in rats of a programming window for reproductive tract masculinization, disruption of which leads to hypospadias and cryptorchidism. *J Clin Invest*. 2008;118:1479-1490.
[78] Gaido KW, Hensley JB, Liu D, Wallace DG, Borghoff S, Johnson KJ, Hall SJ, Boekelheide K. Fetal mouse phthalate exposure shows that Gonocyte multinucleation is not associated with decreased testicular testosterone. *Toxicol Sci*. 2007; 97:491-503.
[79] Lehraiki A, Szenker J, Habert R, Levacher C. *In vivo* and *in vitro* adverse effects of phthalates on fetal and neonatal mouse gonocytes 15th European Testis Workshop. Naantali- Finland Miniposter N° 43. 2008. Available in http://etw15.utu.fi/?id=miniposters&pm=main|miniposters

Folia Histochem Cytobiol. 2009:47(5): S74 (S67-S74)
10.2478/v10042-009-0056-5